{"prompt": "['Acupuncture for Chemotherapy-Induced Peripheral Neuropathy Among Cancer Patients', 'Wake Forest Baptist Comprehensive Cancer Center (WFBCCC)', 'CCCWFU # 97118', 'treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat. 2011;125(3):767-774.', 'doi:10.1007/s10549-010-1278-0', '24. Postma TJ, Aaronson NK, Heimans JJ, et al. The development of an EORTC quality of life', 'questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. Eur J', 'Cancer. 2005;41(8):1135-1139 doi:10.1016/j.ejca.2005.02.012', '25. Lavoie Smith EM, Barton DL, Qin R, Steen PD, Aaronson NK, Loprinzi CL. Assessing patient-', 'reported peripheral neuropathy: the reliability and validity of the European Organization for', 'Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res.', '2013;22(10):2787-2799. bi:10.1007/s11136-013-0379-8', '26. Eckhoff L, Knoop As, Jensen Mb, Ewertz M. Persistence of docetaxel-induced neuropathy and', 'impact on quality of life among breast cancer survivors. Eur J Cancer. 2015;51(3):292-300.', 'doi:10.1016/j.ejca.2014.11.024', '27. Mols F, van de Poll-Franse LV, Vreugdenhil G, et al. Reference data of the European', 'Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in', 'the general Dutch population. Eur J Cancer. 2016;69:28-38. doi:10.1016/j.ejca.2016.09.020', '28. Dueck AC, Mendoza TR, Mitchell SA, et al. Validity and reliability of the US National Cancer', \"Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse\", 'Events (PRO-CTCAE). JAMA Oncol. 2015;1(8):1051. doi:10.1001/jamaoncol.2015.2639', '29.', \"Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute's Patient-\", 'Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-', 'CTCAE). J Natl Cancer Inst. 2014;106(9):dju244-dju244. loi:10.1093/jnci/dju244', '30. Knoerl R, Gray E, Stricker C, et al. Electronic versus paper-pencil methods for assessing', 'chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2017;25(11):3437-3446', 'loi:10.1007/s00520-017-3764-y', '31. Chen X, Stubblefield MD, Custodio CM, Hudis CA, Seidman AD, DeAngelis LM.', 'Electrophysiological features of taxane-induced polyneuropathy in patients with breast cancer. J', 'Clin Neurophysiol Off Publ Am Electroencephalogr Soc. 2013;30(2):199-203.', ':10.1097/NP.0b013e3182767d3b', '32. Argyriou AA, Polychronopoulos P, Iconomou G, Koutras A, Kalofonos HP, Chroni E. Paclitaxel', 'plus carboplatin-induced peripheral neuropathy: A prospective clinical and electrophysiological', 'study in patients suffering from solid malignancies. J Neurol. 2005;252(12):1459-1464.', 'doi:10.1007/s00415-005-0887-8', '33. Argyriou AA, Polychronopoulos P, Koutras A, et al. Clinical and electrophysiological features of', 'peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy.', 'Eur J Cancer Care (Engl). 2007;16(3):231-237.doi:10.1111/j.1365-2354.2006.00718.', 'Page 22 of 55']['Acupuncture for Chemotherapy-Induced Peripheral Neuropathy Among Cancer Patients', 'Wake Forest Baptist Comprehensive Cancer Center (WFBCCC)', 'CCCWFU # 97118', '34. Cavaletti G, Bogliun G, Marzorati L, et al. Grading of chemotherapy-induced peripheral', 'neurotoxicity using the Total Neuropathy Scale. Neurology. 2003;61(9):1297-1300.', 'doi:10.1212/01.WNL.0000092015.03923.19', '35. Park SB, Goldstein D, Lin CS-Y, Krishnan AV, Friedlander ML, Kiernan MC. Acute abnormalities', 'of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol.', '2009;27(8):1243-1249. doi:10.1200/JCO.2008.19.342', '36. Osmani K, Vignes S, Aissi M, et al. Taxane-induced peripheral neuropathy has good long-term', 'prognosis: a 1 - to 13-year evaluation. J Neurol. 2012;259(9):1936-1943. doi:10.1007/s00415-', '012-6442-5', '37. McArthur JC, Stocks EA, Hauer P, Cornblath DR, Griffin JW. Epidermal nerve fiber density:', 'Normative reference range and diagnostic efficiency. Arch Neurol. 1998;55(12):1513.', 'doi:10.1001/archneur.55.12.151', '38. Han Y, Smith MT. Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN).', 'Front Pharmacol. 2013;4. doi:10.3389/fphar.2013.00156', '39. Kr\u00f8ig\u00e4rd T, Schr\u00f8der HD, Qvortrup C, et al. Characterization and diagnostic evaluation of', 'chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to', 'quantitative sensory testing and nerve conduction studies. Eur J Neurol. 2014;21(4):623-629.', 'doi:10.1111/ene.12353', '40. Burakgazi AZ, Messersmith W, Vaidya D, Hauer P, Hoke A, Polydefkis M. Longitudinal', 'assessment of oxaliplatin-induced neuropathy. Neurology. 2011;77(10):980-986.', 'doi:10.1212/WNL.0b013e31822cfc59', '41. Walker FO, Cartwright MS, Wiesler ER, Caress J. Ultrasound of nerve and muscle. Clin', 'Neurophysiol. 2004;115(3):495-507.doi:10.1016/j.clinph.2003.10.022', '42. Cartwright MS, Passmore LV, Yoon J-S, Brown ME, Caress JB, Walker FO. Cross-sectional', 'area reference values for nerve ultrasonography. Muscle Nerve. 2008;37(5):566-571.', 'doi:10.1002/mus.21009', '43. Arumugam T, Razali SNO, Vethakkan SR, Rozalli FI, Shahrizaila N. Relationship between', 'ultrasonographic nerve morphology and severity of diabetic sensorimotor polyneuropathy. Eur J', 'Neurol. 2016;23(2):354-360. bi:10.1111/ene.12836', '44. Chen S, Andary M, Buschbacher R, et al. Electrodiagnostic reference values for upper and lower', 'limb nerve conduction studies in adult populations. Muscle Nerve. 2016;54(3):371-377.', 'doi:10.1002/mus.25203', '45. Lauria G, Devigili G. Skin biopsy as a diagnostic tool in peripheral neuropathy. Nat Clin Pract', 'Neurol. 2007;3(10):546-557. doi:10.1038/ncpneuro0630', 'Page 23 of 55']\n\n###\n\n", "completion": "END"}